Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07422480 · ClinicalTrials.gov registry record · Phase 3
A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
A Phase 3 study of Myelodysplastic Syndrome and Anemia, sponsored by Takeda.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 300
- Enrollment target
- 20
- Study locations
NCT07422480 is a Phase 3 study of Myelodysplastic Syndrome and Anemia that is actively recruiting participants, run by Takeda. The registered enrollment target is 300 participants, above the 205-participant average among 134 other Myelodysplastic Syndrome trials with a reported enrollment target (46% higher). The trial reports 20 study locations across 17 states.
The verdict
NCT07422480, a Phase 3 study of Myelodysplastic Syndrome and Anemia, is actively recruiting participants, sponsored by Takeda.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 300 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main aim of this study is to assess how elritercept works in lowering the need for RBC (red blood cell) transfusions and how safe elritercept is when compared with epoetin alfa. Other aims are to learn if elritercept improves tiredness as reported by participants without needing RBC transfusion compared with epoetin alfa, the RBC transfusion burden and quality of life compared with epoetin alfa. The study also aims to find out the extent of the immune response to elritercept. The study will also check on the medical problems (safety) of elritercept.
Conditions Studied
Interventions
- DRUG Elritercept
- DRUG Epoetin Alfa
Study Locations (20)
Texas
- World Research Link - Baytown
- The Center for Cancer and Blood Disorders - Fort Worth
- The University of Texas-MD Anderson Cancer Center - Leukemia Center - Houston
Tennessee
- Tennessee Oncology, PLLC - Nashville
- Vanderbilt University Medical Center - Nashville
California
- Hematology-Oncology Medical Group of Orange County, Inc - Orange - 1010 W. La Veta Avenue - Orange
Florida
- BRCR Medical Center Inc - Tamarac
Georgia
- Emory University - Atlanta
Illinois
- Orchard Healthcare Research Inc. (OHR) - Skokie - Skokie
Kentucky
- Norton Cancer Institute - Louisville
Missouri
- American Oncology Partners P.A. MidAmerica Cancer Care - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2026-04-01 |
| Est. Completion | 2033-10-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07422480
The ClinicalTrials.gov registry entry for NCT07422480 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 205-participant average among 134 other Myelodysplastic Syndrome trials with a reported enrollment target (46% higher). The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Myelodysplastic Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Elritercept is the first listed.
NCT07422480 reports 20 study locations spanning 17 distinct geographic areas - top geographies include Texas, Tennessee, California.
Frequently Asked Questions
What is clinical trial NCT07422480 about?
NCT07422480 is a clinical study titled "A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions". The main aim of this study is to assess how elritercept works in lowering the need for RBC (red blood cell) transfusions and how safe elritercept is when compared with epoetin alfa. Other aims are to learn if elritercept improves tiredness as reported by participants without needing RBC transfusion ...
What is the current status of trial NCT07422480?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2026-04-01. Estimated completion is 2033-10-01.
What conditions does trial NCT07422480 study?
This clinical trial studies the following conditions: Myelodysplastic Syndrome, Anemia.
What interventions are being tested in trial NCT07422480?
The interventions under investigation include: Elritercept (DRUG), Epoetin Alfa (DRUG).
Who is sponsoring clinical trial NCT07422480?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07422480 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Illinois, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelodysplastic Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome
ACTIVE NOT RECRUITING · Phase 3
-
Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
ACTIVE NOT RECRUITING · Phase 3
-
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome
ACTIVE NOT RECRUITING · Phase 3
-
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
ACTIVE NOT RECRUITING · Phase 3
-
Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD)
COMPLETED · Phase 3
-
IV Busulfan With Allo-BMT: Study for Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome
COMPLETED · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.